Prevention of Resistance: A Goal for Dose Selection for Antimicrobial Agents

Drusano, G.L.
January 2003
Clinical Infectious Diseases;1/15/2003 Supplement 1, Vol. 36, pS42
Academic Journal
Drug-resistant microorganisms have become a major problem around the world. In nosocomial and community settings, many important pathogens have demonstrated high-grade resistance to many of our most important agents. In addition, the adverse impact of resistance has not been limited to the bacterial realm. In chemotherapy to treat human immunodeficiency virus (HIV) and other viral diseases, resistance has become a major problem. We are starting to see the beginnings of a resistance problem, even among fungi. Strangely, little attention has been focused on the impact of dosing on the probability with which emergence of resistance occurs. After delineation of the pharmacodynamically linked variable, it is possible to generate dosing regimens that can lower the probability of resistance. In addition, circumstances exist in which combination therapy may be required (e.g., therapy of HIV and tuberculosis). Here, too, it is possible to optimize therapy to prevent resistance by understanding how the drugs in the regimen interact. We can do better with our choices of dose, schedule, and combinations of agents. We will need to lower the probability of resistance and maintain the utility of the drugs currently in our therapeutic armamentarium.


Related Articles

  • Monitoring Antimicrobial Use and Resistance: Comparison with a National Benchmark on Reducing Vancomycin Use and Vancomycin-Resistant Enterococci. Fridkin, Scott K.; Lawton, Rachel; Edwards, Jonathan R.; Tenover, Fred C.; McGowan Jr., John E.; Gaynes, Robert P. // Emerging Infectious Diseases;Jul2002, Vol. 8 Issue 7, p702 

    Focuses on a study which analyzed data from 50 intensive-care units at 20 U.S. hospitals reporting data on antimicrobial-resistant organisms and antimicrobial agent use, to determine if local monitoring data on vancomycin use directed quality improvement and decreased vancomycin-resistant...

  • Antimicrobial resistance: Bacteria on the defence. Levy, Stuart B. // BMJ: British Medical Journal (International Edition);09/05/98, Vol. 317 Issue 7159, p612 

    Looks at antimicrobial resistance, focussing on the behavior of bacterial agents. Introduction of resistant bacteria from hospital; Results of studies of emerging resistant bacteria; Results of studies concerning resistance in bacteria.

  • Surveillance of antimicrobial resistance. Wale, Martin C.J. // BMJ: British Medical Journal (International Edition);09/05/98, Vol. 317 Issue 7159, p614 

    Looks at the surveillance of antimicrobial resistance, highlighting the gathering of data to approach the problem of antibiotic resistance. Results of centralised testing; Benefits of international cooperation on surveillance of resistance. INSET: A surveillance system for Europe.

  • Antimicrobial resistance in developing countries. Hart, C.A.; Kariuki, S. // BMJ: British Medical Journal (International Edition);09/05/98, Vol. 317 Issue 7159, p647 

    Examines the occurrence of antimicrobial resistance in developing countries. Projects of disability adjusted life; Availability of antimicrobial drugs in developing countries; Description of how antimicrobial drugs are used; Analysis of accute respiratory tract infections.

  • Surveillance of antimicrobial resisitance--an international perspective. Williams, R.J.; Ryan, M.J. // BMJ: British Medical Journal (International Edition);09/05/98, Vol. 317 Issue 7159, p651 

    Discusses the importance of surveillance for containing antimicrobial resistance. Problem of antimicrobial resistance worldwide; Requirements of the surveillance for controlling antimicrobial resistance. INSET: Summary points.

  • Derriere to the Future: Is It Time to Rethink How We Use Antimicrobial Agents? Tillotson, Glenn S. // Clinical Infectious Diseases;4/15/2001, Vol. 32 Issue 8, p1189 

    Addresses problems associated with the emergence of bacterial resistance to antimicrobial agents. Role of frequent low-level use of antibiotics in bacterial resistance; Application of Ehrlich's statement to the use of antibiotics.

  • The microbial threat: Copenhagen recommendations.  // WHO Drug Information;1999, Vol. 13 Issue 1, p12 

    Reports on the recommendations of Ministers of Health from European Union countries during a meeting in Copenhagen, Denmark on the increasing resistance of microorganisms to anti-microbial agents. Need for rational use of anti-microbial agents; Development of new drugs; Surveillance system of...

  • A novel antimicrobial agent joins the battle against resistant bacteria. Moellering Jr., Robert C. // Annals of Internal Medicine;01/19/99, Vol. 130 Issue 2, p155 

    Editorial. Cites the potential of Linezolid as a novel antimicrobial agent that can address the problem of bacterial resistance. Advent of resistant gram-positive bacteria; Chemical modification of known agent; Linezolid's superior pharmacokinetic properties; Bacteriostatic against...

  • Common bacterial pathogens and resistance to antibiotics. Sanderson, P.J. // British Medical Journal (Clinical Research Edition);9/15/1984, Vol. 289 Issue 6446, p638 

    Examines the resistance of common bacterial pathogens to antibiotics in North America. Importance of clinical strategies to combat antibiotic resistance; Aims of antimicrobial treatment; Prevention of cross infection.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics